clinical trial · NCT05011305
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
Nonalcoholic SteatohepatitisFibrosisSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
brief summary
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis
started
Aug 18, 2021
primary completion
Sep 12, 2025
completion
Sep 12, 2025
last updated
Oct 24, 2025
detailed description
A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects with Nonalcoholic Steatohepatitis and Fibrosis.
official title
A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects With Nonalcoholic Steatohepatitis and Fibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol